Many weight-loss medications carry black triangle (▼) status - their real-world safety profiles are still being established. In January 2026, the MHRA issued strengthened safety guidance for GLP-1 receptor agonists regarding severe acute pancreatitis, including fatal cases.¹

These drugs are prescribed at doses higher than the approved maximum for their original use for diabetes - deliberately amplifying a side effect, which also amplifies risk.² In the US, adverse event reports for the two leading weight-loss formulations in this class totalled over 150,000 by August 2025, including more than 1,180 deaths - figures already exceeding the adverse event tolls of earlier weight-loss drugs withdrawn from the market for safety reasons.² 

In the UK, as of April 2026, fatalities and serious reports across 3 medications now used for weight loss was 88,400 adverse events, 14,138 serious reports and 200 deaths.¹

Weight reduction is temporary in most cases. Clinical trial data show that weight regain begins rapidly on cessation, with cardiovascular benefits also reversing - consistent with the broader evidence base for intentional weight loss by any means.² Informed consent must include the temporary nature of weight loss, the strong likelihood of regain, and the absence of long-term evidence supporting indefinite medication use.

Repeated cycles of weight loss and regain carry their own independent health consequences. Evidence from large population studies shows that weight cycling increases cardiovascular risk through mechanisms including hypertension, visceral fat accumulation, insulin resistance, and dyslipidaemia.⁴ In patients with established coronary artery disease, body-weight fluctuation was associated with a 64% higher risk of coronary events, 85% higher risk of cardiovascular events, and 124% higher risk of death compared to those with stable weight, independent of traditional cardiovascular risk factors.⁵ Informed consent must include these risks.

The clinical trials underpinning GLP-1 weight-loss drug approvals have been overwhelmingly funded by - and authored by researchers with direct financial ties to - their manufacturers. A 2026 peer-reviewed analysis found that less favourable trial findings are routinely placed in supplementary materials rather than main papers, to avoid peer review.

The leading manufacturer spent an estimated £22 million in the three years before UK regulatory approval on NHS trusts, universities, and royal colleges - while failing to disclose a further estimated £8 million in payments to individuals involved in the approval process.² Genuine informed consent cannot exist where the evidence base is compromised by undisclosed conflicts of interest.

Social media promotion and celebrity endorsement of weight-loss medications have created serious eating disorder safety risks. An ITV News investigation found that 78% of eating disorder clinics contacted had treated patients who had obtained these medications online.³ Risks are compounded by inadequate prescribing oversight: an estimated 80% of UK users currently obtain these drugs outside NHS channels.²

A weight-centric clinical lens causes diagnostic disparity. Clinicians attribute presenting symptoms to body weight, provide less health education to higher-weight patients, and show reluctance to perform examinations that would identify serious conditions.⁶ Weight stigma is a recognised barrier to timely diagnosis, driving inequalities, healthcare avoidance, delayed presentation, and reduced clinical trust.⁶

This is particularly acute for conditions routinely conflated with higher weight - including hypothyroidism, PCOS, obstructive sleep apnoea, depression, osteoarthritis, and chronic pain - all of which require their own evidenced clinical pathway and will not resolve with weight loss.

Lipoedema and lymphoedema are among the most consistently missed diagnoses in this population. Lipoedema - affecting an estimated 10% of women worldwide - does not respond to diet or weight loss.⁷ Misdiagnosis as generalised "obesity" leads to ineffective mis-management, including weight loss programmes and bariatric surgery, which fail to address the underlying condition.⁸ Only around 30% of GPs in one survey were familiar with lipoedema; misdiagnosis rates may be as high as 80%.⁸˒⁹ Both conditions share overlapping presentations with higher weight and with each other. This knowledge gap creates systematic diagnostic failure for a large population of higher-weight women.⁷

Where weight loss is the default clinical response, the diagnostic process often stops. Equitable care requires that symptoms are investigated on their own terms, and that conditions are named and treated regardless of body size.

Nutriri raises concerns about the absence of equitable weight-neutral alternatives within NHS commissioning frameworks, and the lack of dedicated SNOMED CT coding for weight-neutral care pathways - creating structural inequity at the point of referral. When weight-neutral options are not codeable, they are not fundable, not auditable, and effectively invisible.

Weight stigma is a health disparity in its own right, endemic in healthcare and incompatible with equitable, evidence-based care.⁶ The social determinants of health - income, housing, food access, chronic stress - are unequally distributed. Framing weight as personal choice compounds existing inequalities and obscures their structural causes.

Whether someone is higher weight and in good health, is accessing medications or surgery, is medically contraindicated or does not accept the risks, is post-operative, has stopped medication, lives with an eating disorder, experiences lipoedema, lymphoedema, or other long-term conditions - non-weight surveilling services must be identified and new services created. 

Weight-neutral, stigma-informed care is not contingent on weight-change decisions. It is simply good care.

Where a person does not smoke, reduces alcohol, balances nutrition, and moves regularly, all-cause mortality is near-equal across the bodyweight spectrum.¹⁰ Nutriri's work supports this - shifting the signal from a “weight-equals-health infodemic” towards health-supporting clarity, equity, and better outcomes at every size.

1. MHRA (2026). GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases. Drug Safety Update, 19(6). https://www.gov.uk/drug-safety-update/glp-1-receptor-agonists-and-dual-glp-1-slash-gip-receptor-agonists-strengthened-warnings-on-acute-pancreatitis-including-necrotising-and-fatal-cases

2. Chastain R, Meadows A, Adams L. (2026). GLP-1 medications for weight-loss: a triumph of marketing over patient care. Fat Studies. https://doi.org/10.1080/21604851.2026.2646492

3. Tew A, Shah C. (2026). The dark side of the 'miracle jab': why eating disorder safety cannot be an afterthought. The Pharmaceutical Journal, 317(8006). https://doi.org/10.1211/PJ.2026.1.395589

4. Montani J-P, Viecelli AK, Prévot A, Dulloo AG. (2006). Weight cycling during growth and beyond as a risk factor for later cardiovascular diseases: the 'repeated overshoot' theory. International Journal of Obesity, 30(Suppl 4), S58–S66. https://doi.org/10.1038/sj.ijo.0803520

5. Bangalore S, Fayyad R, Laskey R, DeMicco DA, Messerli FH, Waters DD. (2017). Body-weight fluctuations and outcomes in coronary disease. New England Journal of Medicine, 376(14), 1332–1340. https://doi.org/10.1056/NEJMoa1606148

6. Phelan SM, et al. (2015). Impact of weight bias and stigma on quality of care and outcomes for patients with obesity. Obesity Reviews, 16(4), 319–26. https://doi.org/10.1111/obr.12266

7. Cifarelli V, et al. (2025). Lipedema: progress, challenges, and the road ahead. Obesity Reviews. https://doi.org/10.1111/obr.13953

8. Buso G, et al. (2019). Lipedema: a call to action! Obesity, 27(10). https://doi.org/10.1002/oby.22597

9. Mortada M, et al. (2025). Lipedema and adipose tissue: current understanding, controversies, and future directions. Frontiers in Cell and Developmental Biology. https://doi.org/10.3389/fcell.2025.1691161

10. Matheson EM, King DE, Everett CJ. (2012). Healthy lifestyle habits and mortality in overweight and obese individuals. Journal of the American Board of Family Medicine, 25(1), 9–15. https://doi.org/10.3122/jabfm.2012.01.110164